Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 13, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
Changes in share interests were reported for three individuals due to the re-investment of dividends paid on April 12, 2007, at a price of $57.07 per share under the Annual Investment Plan feature:
- Dr. JP Garnier: Increase of 387.74 Ordinary Share ADRs
- Dr. D Pulman: Increase of 20.89 Ordinary Share ADRs
- Mr. D Stout: Increase of 318.12 Ordinary Share ADRs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of specific director transactions.
Investor Verification Points
- Confirm the dividend re-investment price of $57.07 per share.
- Verify the specific increase in Ordinary Share ADRs for Dr. JP Garnier, Dr. D Pulman, and Mr. D Stout.
- Note that this filing does not contain financial performance data for the period.